{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:45:37Z","timestamp":1791179137866,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The novel prodrug of butyric acid, pivaloyloxymethyl butyrate (AN-9), a histone deacetylase inhibitor, shows great promise as an effective and relatively nontoxic anticancer agent for solid malignancies. However, little is known about its effects on hematopoietic malignancies. In this study, we show that 21 primary samples of acute leukemia were sensitive to the antiproliferative effects of AN-9, with a 50% inhibitory concentration (IC50) of 45.8\u2009\u00b1\u20094.1 \u03bcM. In colony-forming assays, primary T-cell acute lymphoblastic leukemia (T-ALL) cells were 3-fold more sensitive to AN-9 than the normal hematopoietic progenitors, erythroid burst-forming units and granulocyte\/monocyte colony-forming units. AN-9 induced apoptosis in the T-ALL cell line CEM. A common problem with cancer is chemoresistance, which is often typical of relapsed cancers. Remarkably, a T-ALL sample at diagnosis and an acute myeloid leukemia sample at relapse that were resistant to doxorubicin in vitro were sensitive to AN-9, with an IC50 of 50 \u03bcM for both samples. More strikingly, samples from 2 infants with t(4;11) ALL obtained at diagnosis and relapse each were the most sensitive to AN-9, with IC50values of 25 \u03bcM and 17 \u03bcM, respectively. Furthermore, a doxorubicin-resistant clone of HL60, HL60\/ADR, obtained by the transfection of the MDR-1 gene, was equally sensitive to AN-9 cytotoxicity as the parental cells. AN-9 induced the expression of p21 in an infant leukemia sample with 11q23 rearrangement, but not in T- or B-precursor ALL. Collectively, our results suggest that AN-9 is a selective agent for hematopoietic malignancies that can circumvent the mechanisms of chemoresistance limiting most conventional chemotherapy.<\/jats:p>","DOI":"10.1182\/blood-2002-02-0567","type":"journal-article","created":{"date-parts":[[2002,10,16]],"date-time":"2002-10-16T19:03:08Z","timestamp":1034794988000},"page":"3319-3324","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines"],"prefix":"10.1182","volume":"100","author":[{"given":"Ayse","family":"Batova","sequence":"first","affiliation":[{"name":"From the Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of California San Diego; Department of Immunology, The Scripps Research Institute, La Jolla, CA; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel; and the Chemistry Department, Bar Ilan University, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-en","family":"Shao","sequence":"additional","affiliation":[{"name":"From the Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of California San Diego; Department of Immunology, The Scripps Research Institute, La Jolla, CA; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel; and the Chemistry Department, Bar Ilan University, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell B.","family":"Diccianni","sequence":"additional","affiliation":[{"name":"From the Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of California San Diego; Department of Immunology, The Scripps Research Institute, La Jolla, CA; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel; and the Chemistry Department, Bar Ilan University, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice L.Yu, Tetsuya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"From the Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of California San Diego; Department of Immunology, The Scripps Research Institute, La Jolla, CA; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel; and the Chemistry Department, Bar Ilan University, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Rephaeli","sequence":"additional","affiliation":[{"name":"From the Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of California San Diego; Department of Immunology, The Scripps Research Institute, La Jolla, CA; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel; and the Chemistry Department, Bar Ilan University, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Nudelman","sequence":"additional","affiliation":[{"name":"From the Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of California San Diego; Department of Immunology, The Scripps Research Institute, La Jolla, CA; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel; and the Chemistry Department, Bar Ilan University, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yu","sequence":"additional","affiliation":[{"name":"From the Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of California San Diego; Department of Immunology, The Scripps Research Institute, La Jolla, CA; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel; and the Chemistry Department, Bar Ilan University, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111616300051000_B1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription.","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature."},{"key":"2019111616300051000_B2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.51.5.786","article-title":"Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis.","volume":"61","author":"Allfrey","year":"1964","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111616300051000_B3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0092-8674(00)80211-1","article-title":"What's up and down with histone deacetylation and transcription?","volume":"89","author":"Pazin","year":"1997","journal-title":"Cell."},{"key":"2019111616300051000_B4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"2019111616300051000_B5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1093\/emboj\/18.9.2449","article-title":"The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.","volume":"18","author":"Brehm","year":"1999","journal-title":"EMBO J."},{"key":"2019111616300051000_B6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/73536","article-title":"Mutations truncating the EP300 acetylase in human cancers.","volume":"24","author":"Gayther","year":"2000","journal-title":"Nat Genet."},{"key":"2019111616300051000_B7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/35901","article-title":"Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia.","volume":"391","author":"Grignani","year":"1998","journal-title":"Nature."},{"key":"2019111616300051000_B8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/35895","article-title":"Role of the histone deacetylase complex in acute promyelocytic leukemia.","volume":"391","author":"Lin","year":"1998","journal-title":"Nature."},{"key":"2019111616300051000_B9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ng0298-126","article-title":"Distinct interactions of PML-RARalpha and PLZF-RARalpha with corepressors determine differential responses to RA in APL.","volume":"18","author":"He","year":"1998","journal-title":"Nat Genet."},{"key":"2019111616300051000_B10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","article-title":"Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.","volume":"90","author":"Warrel","year":"1998","journal-title":"J Natl Cancer Inst."},{"key":"2019111616300051000_B11","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","article-title":"A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo anti-tumor activity against human tumors.","volume":"96","author":"Saito","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111616300051000_B12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9","article-title":"Effect of trichostatin A on cell growth and expression of cell cycle and apoptosis-related molecules in human gastric and oral carcinoma cell lines.","volume":"88","author":"Suzuki","year":"2000","journal-title":"Int J Cancer."},{"key":"2019111616300051000_B13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/jm00082a009","article-title":"Novel anticancer prodrugs of butyric acid.","volume":"35","author":"Nudelman","year":"1992","journal-title":"J Med Chem."},{"key":"2019111616300051000_B14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF01208637","article-title":"Effect of butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells.","volume":"123","author":"Aviram","year":"1997","journal-title":"J Cancer Res Clin Oncol."},{"key":"2019111616300051000_B15","first-page":"579a","article-title":"Pivaloyloxymethyl butyrate (AN-9) exhibits higher anticancer activity than butyric acid (BA): it penetrates faster than the acid and induces apoptosis in HL60 cells.","volume":"84","author":"Zimra","year":"1994","journal-title":"Blood."},{"key":"2019111616300051000_B16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ijc.2910490113","article-title":"Derivatives of butyric acid as potential anti-neoplastic agents.","volume":"49","author":"Rephaeli","year":"1991","journal-title":"Int J Cancer."},{"key":"2019111616300051000_B17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1006049227744","article-title":"Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.","volume":"16","author":"Siu","year":"1998","journal-title":"Invest New Drugs."},{"key":"2019111616300051000_B18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF01214667","article-title":"Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL60 cells.","volume":"123","author":"Zimra","year":"1997","journal-title":"J Cancer Res Clin Oncol."},{"key":"2019111616300051000_B19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bjc.1997.151","article-title":"An anticancer derivative of butyric acid (pivaloyloxymethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukemia cells.","volume":"75","author":"Kasukabe","year":"1997","journal-title":"Br J Cancer."},{"key":"2019111616300051000_B20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002800050627","article-title":"Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells.","volume":"40","author":"Kelner","year":"1997","journal-title":"Cancer Chemother Pharmacol."},{"key":"2019111616300051000_B21","first-page":"5080","article-title":"doxorubicin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drugsensitive cells.","volume":"47","author":"Marsh","year":"1987","journal-title":"Cancer Res."},{"key":"2019111616300051000_B22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0022-3468(91)90684-L","article-title":"Multidrug resistance in human neuroblastoma cells.","volume":"26","author":"LaQuaglia","year":"1991","journal-title":"J Pediatr Surg."},{"key":"2019111616300051000_B23","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1073\/pnas.95.12.6791","article-title":"p21waf1 is required for butyrate-mediated growth inhibition of human colon cancer cells.","volume":"95","author":"Archer","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111616300051000_B24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/carcin\/21.1.7","article-title":"Involvement of p21(Waf1\/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.","volume":"21","author":"Chai","year":"2000","journal-title":"Carcinogenesis."},{"key":"2019111616300051000_B25","first-page":"507","article-title":"A phase I study of AN-9 (pivaloyloxymethyl butyrate, PivanexTM), a lipophilic butyric acid analog, in patients with advanced solid tumors.","volume":"39","author":"Eckhardt","year":"1998","journal-title":"Proc Am Assoc Cancer Res."},{"key":"2019111616300051000_B26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0145-2126(87)90112-3","article-title":"Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging.","volume":"11","author":"Singer","year":"1987","journal-title":"Leuk Res."},{"key":"2019111616300051000_B27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jnci\/66.6.1053","article-title":"Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents.","volume":"66","author":"Spiro","year":"1981","journal-title":"J Natl Cancer Inst."},{"key":"2019111616300051000_B28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0609.1993.tb00083.x","article-title":"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L).","volume":"50","author":"Linssen","year":"1993","journal-title":"Eur J Haematol."},{"key":"2019111616300051000_B29","first-page":"465","article-title":"Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals.","volume":"9","author":"Vaziri","year":"1998","journal-title":"Cell Growth Differ."},{"key":"2019111616300051000_B30","first-page":"3697","article-title":"Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase). Dependence on protein synthesis and synergy with a mitochondrial\/cytochrome c-dependent pathway.","volume":"57","author":"Medina","year":"1997","journal-title":"Cancer Res."},{"key":"2019111616300051000_B31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.cdd.4400371","article-title":"Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate.","volume":"5","author":"Bonnotte","year":"1998","journal-title":"Cell Death Differ."},{"key":"2019111616300051000_B32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1097-0215(19990105)80:1<145::AID-IJC26>3.0.CO;2-G","article-title":"Frequent deregulation of p16 and the p16\/G1 cell cycle-regulatory pathway in neuroblastoma.","volume":"80","author":"Diccianni","year":"1999","journal-title":"Int J Cancer."},{"key":"2019111616300051000_B33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/mol.58.1.27","article-title":"Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity.","volume":"58","author":"Niitsu","year":"2000","journal-title":"Mol Pharmacol."},{"key":"2019111616300051000_B34","first-page":"8194","article-title":"Molecular basis for the synergistic interaction of doxorubicin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).","volume":"61","author":"Cutts","year":"2001","journal-title":"Cancer Res."},{"key":"2019111616300051000_B35","doi-asserted-by":"crossref","first-page":"11561","DOI":"10.1073\/pnas.95.20.11561","article-title":"Characterization of covalent doxorubicin-DNA adducts.","volume":"95","author":"Zeman","year":"1998","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/9\/3319\/1257057\/h82102003319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/9\/3319\/1257057\/h82102003319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T16:30:16Z","timestamp":1573921816000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/9\/3319\/16359\/The-histone-deacetylase-inhibitor-AN9-has"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,11,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-02-0567","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}